Risk factors for Mycobacterium chelonae-abscessus pulmonary disease persistence and deterioration

Journal of Infection

Volumn 64, Issue 2, 2012, Pages 228-230

  Lee, Meng Rui ^a,b   Keng, Li Ta ^a   Shu, Chin Chung ^a   Lee, Shih Wei ^b   Lee, Chih Hsin ^c   Wang, Jann Yuan ^a   Lee, Li Na ^a   Yu, Chong Jen ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAO YUAN GENERAL HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; IMIPENEM; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACID FAST BACTERIUM; ADULT; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; INFECTION RISK; LETTER; LUNG INFECTION; LUNG STRUCTURE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; PATIENT MONITORING; RISK ASSESSMENT; RISK FACTOR; SPUTUM SMEAR; TREATMENT DURATION;

FEMALE; HUMANS; MALE; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS;

EID: 84855904123     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.11.006     Document Type: Letter

References (9)

1. van Ingen J., de Zwaan R., Dekhuijzen R.P., Boeree M.J., van Soolingen D. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect 2009, 59:324-331.
2. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
3. Jeon K., Kwon O.J., Lee N.Y., Kim B.J., Kook Y.H., Lee S.H., et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009, 180:896-902.
4. Kim R.D., Greenberg D.E., Ehrmantraut M.E., Guide S.V., Ding L., Shea Y., et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008, 178:1066-1074.
5. Chu N.F., Wang S.C., Chang H.Y., Wu D.M. Medical Services utilization and expenditure of obesity-related disorders in Taiwanese adults. Value Health 2010, 13:829-836.
6. Wang C.C., Lin M.C., Liu J.W., Wang Y.H. Nontuberculous mycobacterial lung disease in southern Taiwan. Chang Gung Med J 2009, 32:499-508.
7. Lin H.P., Deng C.Y., Chou P. Diagnosis and treatment delay among pulmonary tuberculosis patients identified using the Taiwan reporting enquiry system, 2002-2006. BMC Public Health 2009, 9:55.
8. Sexton P., Harrison A.C. Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008, 31:1322-1333.
9. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997, 156:S1-S25. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association.